• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疫苗成本效益分析中的生产力损失/收益:系统评价。

Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review.

机构信息

Pfizer Japan Inc., Tokyo, Japan.

Graduate School of Medicine, International University of Health and Welfare, Tokyo, Japan.

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):235-245. doi: 10.1080/14737167.2021.1881484. Epub 2021 Feb 23.

DOI:10.1080/14737167.2021.1881484
PMID:33593223
Abstract

: The kinds of costs included in cost-effectiveness analyses (CEAs) for vaccines, such as direct medical costs and indirect costs, may affect their outcomes. While some guidelines recommend inclusion of costs associated with productivity losses/gains, very little guidance is provided about the productivity elements to include and their calculation approach.: We conducted a systematic review of CEAs for vaccines and vaccine programs published between 1 January 2010 and 19 November 2019 that included productivity costs using Medline, Embase, and the Cochrane Library. The kind of productivity elements included their calculation approach, and the impact of their inclusion on cost-effectiveness are summarized. Among 88 studies identified, productivity elements included were reported for 71 studies (81%) with absenteeism being the most commonly included element. Only 24 studies (27%) reported the approach used to calculate productivity costs (human capital vs. friction approach). Most studies (81%) reported a more favorable cost-effectiveness with the inclusion of productivity losses/gains.: Inclusion of productivity losses/gains for CEAs for vaccines has resulted in more favorable cost-effectiveness based on the studies reviewed. However, clearer guidance on the productivity elements to include by disease area and more transparency on the calculation method used may be needed.

摘要

疫苗成本效益分析(CEA)中包含的成本种类,如直接医疗成本和间接成本,可能会影响其结果。虽然一些指南建议纳入与生产力损失/收益相关的成本,但对于纳入哪些生产力要素以及如何计算,几乎没有提供任何指导。

我们对 2010 年 1 月 1 日至 2019 年 11 月 19 日期间发表的使用 Medline、Embase 和 Cochrane 图书馆的疫苗和疫苗计划 CEA 进行了系统回顾,其中包含使用生产力成本。总结了纳入的生产力要素及其计算方法,以及它们对成本效益的影响。在确定的 88 项研究中,有 71 项(81%)报告了生产力要素,其中缺勤是最常报告的要素。只有 24 项研究(27%)报告了计算生产力成本的方法(人力资本与摩擦方法)。大多数研究(81%)报告说,纳入生产力损失/收益会使成本效益更有利。

纳入疫苗 CEA 的生产力损失/收益,根据审查的研究,使成本效益更有利。然而,可能需要根据疾病领域更明确地指导纳入哪些生产力要素,以及更透明地说明使用的计算方法。

相似文献

1
Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review.疫苗成本效益分析中的生产力损失/收益:系统评价。
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):235-245. doi: 10.1080/14737167.2021.1881484. Epub 2021 Feb 23.
2
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review.药物成本效益分析中使用生产效率损失/增益:系统评价。
Pharmacoeconomics. 2021 Jan;39(1):81-97. doi: 10.1007/s40273-020-00986-4. Epub 2020 Nov 24.
3
Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.免疫介导性疾病成本效益分析中使用生产力损失/增益的系统文献回顾。
Adv Ther. 2022 Dec;39(12):5327-5350. doi: 10.1007/s12325-022-02321-z. Epub 2022 Oct 7.
4
[Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].[药物经济学分析中生产力损失的成本。第一部分。文献系统综述]
Przegl Epidemiol. 2011;65(1):147-52.
5
Productivity losses associated with cardiovascular disease: a systematic review.与心血管疾病相关的生产力损失:一项系统综述。
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):759-769. doi: 10.1080/14737167.2016.1259571. Epub 2016 Nov 21.
6
Productivity loss due to overweight and obesity: a systematic review of indirect costs.超重和肥胖导致的生产力损失:间接成本的系统评价
BMJ Open. 2017 Oct 5;7(10):e014632. doi: 10.1136/bmjopen-2016-014632.
7
How to estimate productivity costs in economic evaluations.如何在经济评估中估算生产力成本。
Pharmacoeconomics. 2014 Apr;32(4):335-44. doi: 10.1007/s40273-014-0132-3.
8
A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?工作场所干预措施经济评估中的生产力系统评价:是否需要报告标准?
Appl Health Econ Health Policy. 2019 Oct;17(5):591-613. doi: 10.1007/s40258-019-00473-8.
9
Productivity-cost controversies in cost-effectiveness analysis: review and research agenda.成本效益分析中的生产率-成本争议:综述与研究议程
Clin Ther. 1999 Jan;21(1):255-67. doi: 10.1016/S0149-2918(00)88283-1.
10
Systematic review of studies on rotavirus disease cost-of-illness and productivity loss in Latin America and the Caribbean.拉丁美洲和加勒比地区轮状病毒疾病疾病负担和生产力损失研究的系统评价。
Vaccine. 2013 Jul 2;31 Suppl 3:C45-57. doi: 10.1016/j.vaccine.2013.05.031.

引用本文的文献

1
The cost-effectiveness of COVID-19 vaccination program among age-groups children, adults, and elderly in Europe: A systematic review.欧洲儿童、成人和老年人年龄组中COVID-19疫苗接种计划的成本效益:一项系统综述。
Vaccine X. 2024 Nov 8;21:100580. doi: 10.1016/j.jvacx.2024.100580. eCollection 2024 Dec.
2
The economic burden of varicella among children in France: a caregiver survey.法国儿童水痘的经济负担:一项照顾者调查。
Eur J Pediatr. 2024 Dec;183(12):5233-5243. doi: 10.1007/s00431-024-05763-5. Epub 2024 Oct 5.
3
A Systematic Review of Methods for Estimating Productivity Losses due to Illness or Caregiving in Low- and Middle-Income Countries.
低、中收入国家因病缺勤和照顾病患导致生产力损失的估算方法系统评价
Pharmacoeconomics. 2024 Aug;42(8):865-877. doi: 10.1007/s40273-024-01402-x. Epub 2024 Jun 14.
4
Economic burden of varicella in Bangkok, Thailand: A multicenter medical chart review study.泰国曼谷水痘的经济负担:一项多中心医学图表回顾研究。
PLOS Glob Public Health. 2024 Jun 12;4(6):e0003099. doi: 10.1371/journal.pgph.0003099. eCollection 2024.
5
New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement.新型疫苗平台——经济与社会价值的新维度及其衡量
Vaccines (Basel). 2024 Feb 24;12(3):234. doi: 10.3390/vaccines12030234.
6
Development of the Indian Reference Case for undertaking economic evaluation for health technology assessment.用于卫生技术评估的印度参考案例的制定。
Lancet Reg Health Southeast Asia. 2023 Jun 17;16:100241. doi: 10.1016/j.lansea.2023.100241. eCollection 2023 Sep.
7
Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.免疫介导性疾病成本效益分析中使用生产力损失/增益的系统文献回顾。
Adv Ther. 2022 Dec;39(12):5327-5350. doi: 10.1007/s12325-022-02321-z. Epub 2022 Oct 7.
8
Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China.将生产力损失纳入健康经济评估:对全球指南和实践的综述,以及对中国研究议程的启示。
BMJ Glob Health. 2022 Aug;7(8). doi: 10.1136/bmjgh-2022-009777.
9
Economic evaluations of interventions against viral pandemics: a scoping review.干预病毒性大流行的经济评估:范围综述。
Public Health. 2022 Jul;208:72-79. doi: 10.1016/j.puhe.2022.05.001. Epub 2022 Jun 17.
10
The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.在英国将基于细胞的流感疫苗接种扩大至50至64岁低风险成年人的成本效益分析
Vaccines (Basel). 2021 Jun 4;9(6):598. doi: 10.3390/vaccines9060598.